INTS, Disruptor in oncology

This is probably one of the easiest biotech picks I've done. The candidate drug INT230-6 has 3 components: Cisplastin and Vinblastine are already approved oncology drugs and delivery molecule that allows drug to be injected directly into tumor. It is the only non covalent binding injection drug there is. Non covalent means that molecule of drug is not connected to delivery molecule, therefore it's pharmacological effect is unchanged, predictable. All of their preliminary results are absolutely stellar. From their most recent findings in TNBC, they've shown higher efficiency and 50% less safety issues than standard of care. More importantly the company is saying that drug is so effective that they might change the standard of care to remove Doxorubicin, nicknamed 'Red Devil' for its destructive side effects. This is absolutely huge. What is so good about this company it is not really proving that those drugs are effective, they have been for decades. They only need to show the effectiveness of their delivery system which is more akin to medical engineering rather than pure pharma. And medical engineering is much more stable in repeating early results, if delivery molecule works, it works. And it is also a platform company. If they prove that their delivery platform DfuseRx work, it might resurrect many drugs that were too toxic to be used and are collecting dust as IP of big Pharma. Makes it a major acquisition target. Here is a link to a recent interview with ceo: https://www.drugdiscoveryonline.com/doc/how-can-we-develop-new-treatments-for-patients-with-early-breast-cancer-0001